Hyderabad: CII Telangana in association with IMT Hyderabad organized a Health & Pharma Conclave, here at Hyderabad today. The Conclave discussed the leadership role in bringing efficiencies and addressed current challenges that are plaguing the Pharmaceutical Sector.
In his Inaugural Address, Etala Rajender, Hon’ble Minister of Health, Medical & Family Welfare, Government of Telangana said that Health and Education are the two priority areas for the government and the government is working towards making Telangana a Healthy State.
Highlighting the need for affordable healthcare, the Minister said that good healthcare services should be available to common people. Countries that have focussed on good healthcare have always become progressive. Technology should be used well to increase the access and quality of healthcare, he said.
Telangana is already a Hub for Pharma & Biotech Industry and the government will provide all support to the industries to grow & flourish. The government also intends to be the leading State in the Country for providing good & affordable healthcare.
Speaking at the Inaugural Session of the Conclave GV Prasad, Chairman, CII National Committee on Pharmaceuticals & Co-Chairman & CEO, Dr Reddy’s Laboratories Ltd said that as a nation we have to invest in Primary care, prevention and screening a lot more.
Prasad opined that access and affordability of healthcare is not a huge issue in India, but the main issue is of lack of robust insurance system and less emphasis on Primary healthcare and prevention.
The Pharma & Healthcare industry has progressed really well, the industry has found solutions to many deadly diseases today.
India rates the lowest among the price points in the world, he said. The Pharma industry in the country is doing really well. After the IT Services sector, the Pharma sector is the most globally competitive, he said. The IT Services sector in Hyderabad is uniquely positioned to support the transaction of the Pharmaceutical industry to Industry 4.0 with Digitization, Automation, and AI.
In his Special Address, E V Narasimha Reddy, Vice Chairman & Managing Director, TSIIC, Government of Telangana said that the Government of Telangana has implemented various welfare Schemes for healthcare in the State. Telangana has the right ecosystem will the availability of world-class infrastructure. The government has adopted a Cluster approach to developing the Pharma & Healthcare in the State. The 9000 acres Phase I Pharma city is already developed. It is an inclusive Cluster that will have API, Formulations, Academia and a Pharma University. Also, Media Devices Park has been developed.
The Government also aims to make Hyderabad the capital of Healthcare. With the Network of best hospitals in the State this also will be achieved soon, he said. The government is also encouraging R&D in pharma manufacturing with the aim to reduce manufacturing costs and making healthcare affordable. Disruptive Technologies for the better healthcare system and usage of AI for reduction of treatment time will also help to reduce cost, he said. But Facilities need to be improved and Awareness Creation is important to prevent many diseases.
Prof (Dr) M Venkateshwarlu, Director, IMT-Hyderabad in his address said that IMT is working on Learner Centric programs and working closely with industry for curriculum development.
Earlier delivering his welcome remarks D Raju, Chairman, CII Telangana & CEO & MD, Kirby Building Systems said that with the increasing population of the country the stress on healthcare resources will be immense. The government of India and Telangana has laid a lot of emphasis on affordable healthcare with schemes like Ayushman Bharat and Arogyasri. Technology will be the game-changer for the pharmaceutical & healthcare industry he said.
A Healthcare and Pharma report was unveiled at the Conclave. The report details the emerging trends in the healthcare and pharma industry in India from three aspects: Digital Marketing, Analytics, Diversity, and Inclusion. The report is based on secondary research and primary interactions with industry stakeholders.
SOURCE: (NSS)
